Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Profit After Tax (2016 - 2026)

Pharma-Bio Serv's Profit After Tax history spans 17 years, with the latest figure at -$94535.0 for Q1 2026.

  • For Q1 2026, Profit After Tax fell 1207.49% year-over-year to -$94535.0; the TTM value through Jan 2026 reached -$530379.0, up 47.4%, while the annual FY2025 figure was -$637662.0, 50.48% up from the prior year.
  • Profit After Tax reached -$94535.0 in Q1 2026 per PBSV's latest filing, up from -$133272.0 in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $526242.0 in Q3 2023 to a low of -$493857.0 in Q4 2024.
  • Average Profit After Tax over 5 years is $28443.4, with a median of -$47148.0 recorded in 2023.
  • Peak YoY movement for Profit After Tax: skyrocketed 107.01% in 2022, then plummeted 1207.49% in 2026.
  • A 5-year view of Profit After Tax shows it stood at $341640.0 in 2022, then plummeted by 113.8% to -$47148.0 in 2023, then tumbled by 947.46% to -$493857.0 in 2024, then skyrocketed by 73.01% to -$133272.0 in 2025, then rose by 29.07% to -$94535.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Profit After Tax are -$94535.0 (Q1 2026), -$133272.0 (Q4 2025), and -$204250.0 (Q3 2025).